The role of statins in endothelial dysfunction in hypertension

被引:22
作者
Sarkar, Kunal
Sinha, Anjan K.
Mehta, Jawahar L.
机构
[1] Univ Arkansas Med Sci, Div Cardiovasc Med, Little Rock, AR 72205 USA
[2] Cent Arkansas Vet Healthcare Ctr, Little Rock, AR USA
关键词
dyslipidemia; endothelial dysfuntion; hypertension; oxidative stress; statins;
D O I
10.1097/01.hco.0000231401.87232.71
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Hypertension and dyslipidemia frequently coexist, and endothelial dysfunction is associated with the pathophysiology of both atherosclerosis and hypertension. Evidence is convincing for an overlapping role of oxidative stress, renin-angiotensin system activation, and dyslipidemia in the genesis of endothelial dysfunction. Recent findings Ample experimental and human data suggest that common cellular pathways are involved in the pathogenesis of hypertension, increased vascular resistance, and plaque formation. Multiple interventions, such as dietary modification, exercise, antioxidants, and antihypertensive drugs improve endothelial dysfunction in hypertension. Statin drugs are a cornerstone of dyslipidemia therapy. Studies have demonstrated that statins correct endothelial function and vascular stiffening and may be useful in reducing blood pressure to target levels. Summary Statins may be a useful adjunct in the treatment of hypertension in patients, with dyslipidemia and possibly those with normal cholesterol levels.
引用
收藏
页码:316 / 321
页数:6
相关论文
共 51 条
[1]  
Abetel G, 1998, SCHWEIZ MED WSCHR, V128, P272
[2]   Flow-mediated vasodilation and distensibility in relation to intima-media thickness of large arteries in mild essential hypertension [J].
Barenbrock, M ;
Hausberg, M ;
Kosch, M ;
Golubev, SA ;
Kisters, K ;
Rahn, KH .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (10) :973-979
[3]   Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats [J].
Bolterman, RJ ;
Manriquez, MC ;
Ruiz, MCO ;
Juncos, LA ;
Romero, JC .
HYPERTENSION, 2005, 46 (04) :943-947
[4]   Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia [J].
Borghi, C ;
Prandin, MG ;
Costa, FV ;
Bacchelli, S ;
Degli Esposti, D ;
Ambrosioni, E .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (04) :549-555
[5]   Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice - Novel insights into the role of RAS and dyslipidemid in atherogenesis [J].
Chen, JW ;
Li, DY ;
Schaefer, RF ;
Mehta, JL .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 (04) :446-452
[6]   Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice [J].
Daugherty, A ;
Cassis, L .
THE METABOLIC SYNDROME X: CONVERGENCE OF INSULIN RESISTANCE, GLUCOSE INTOLERANCE, HYPERTENSION, OBESITY, AND DYSLIPIDEMIAS-SEARCHING FOR THE UNDERLYING DEFECTS, 1999, 892 :108-118
[7]   Candesartan reduces oxidative stress and inflammation in patients with essential hypertension [J].
Dohi, Y ;
Ohashi, M ;
Sugiyama, M ;
Takase, H ;
Sato, K ;
Ueda, R .
HYPERTENSION RESEARCH, 2003, 26 (09) :691-697
[8]   Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension [J].
Ferrier, KE ;
Muhlmann, MH ;
Baguet, JP ;
Cameron, JD ;
Jennings, GL ;
Dart, AM ;
Kingwell, BA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (06) :1020-1025
[9]   Simvastatin decreases aldehyde production derived from lipoprotein oxidation [J].
Girona, J ;
La Ville, AE ;
Solà, R ;
Plana, N ;
Masana, L .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (06) :846-851
[10]   Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia [J].
Glorioso, N ;
Troffa, C ;
Filigheddu, F ;
Dettori, F ;
Soro, A ;
Parpaglia, PP ;
Collatina, S ;
Pahor, M .
HYPERTENSION, 1999, 34 (06) :1281-1286